The 6th Biologics World Nordics 2023 event will bring together biologic and biosimilar developers and manufacturers, technology providers, CMOs and CROs from the Nordics region and beyond to explore partnership and technical collaboration opportunities, discuss best R&D and biomanufacturing practises, and debate growth strategies as Nordics developed biologics enter critical clinical phase II and III development stages.
This is the only biologics market place in the Nordics area that demonstrates the region's enormous possibilities and provides a full network for Nordic biologic firms wishing to license/partner with large pharma, CROs, and CDMO/CMOs.
Clinical Trials of Biologics & Cell & Gene Therapy Products from Nordics Region
The Nordics region is playing a critical role in expanding medical knowledge and opening the path for revolutionary medicines that hold promise for patients globally. Explore the exciting progress of clinical studies on biologics and cell and gene therapy products from the Nordics biopharma.
High-Throughput Cell Line Development & Cell Culture
High-throughput cell line creation and cell culture have considerably sped the discovery and development of novel biologics, improving the efficiency and scalability of biopharmaceutical manufacturing. Know-how on the latest development of cell line development and cell culture technologies have evolved and potentially changed the biologics drug manufacturing process to be more economically feasible.
Cost Optimisation & Advanced Purification Platforms
Cost optimisation strategies coupled with the utilisation of advanced purification platforms have become essential for the biopharmaceutical industry, enabling efficient and economical production of high-quality therapeutics. Immerse into the most focused biologics downstream processing with the ultimate goal of meeting quality and purity requirements of biologics drug products at lower cost.
Commercialising the R&D Priorities in the Nordics Region
Listen from the Nordic region which demonstrated exceptional process in commercialising its R&D objectives, capitalising on its strong innovation ecosystem, supportive regulatory framework, and strategic alliances to translate cutting-edge research into marketable products and solutions.
Opportunities in the Nordics Biologics Sector, Exploring Growth, Innovation, and Collaboration
The Nordic biologics sector is poised to drive transformative advances in medicine, create new market opportunities, and address unmet medical needs on a global scale by leveraging the region's expertise in biologics R&D and manufacturing, cutting-edge research capabilities, and collaborative approach to healthcare innovation.
Emerging Technologies and Applications: New Modalities, Platform & Technologies
Novel emerging technologies such gene editing and RNA-based therapeutics, have enormous potential for improving patient outcomes, driving precision medicine, and altering the healthcare landscape in the future.
Bioneer is an innovative Danish specialty CRO/CMO, creating customized research service solutions to meet our clients’ needs. We help you develop and produce your promising early drug candidates from as early on as their inception and generate key early insights into their mechanisms, efficacy, and safety. A trusted strategic R&D partner to biotech and pharmaceutical companies since 1982, we bring value with our unique know-how and advanced technologies.
GenScript is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
For more information, visit www.genscript.com
Pall Corporation provides critical filtration, separation, and purification solutions to meet the demanding needs of a broad spectrum of life sciences and industrial customers around the globe. Across 80 locations and 10,000 people worldwide, we are unified by a singular drive: to solve our customers' biggest fluid management challenges. And in doing so advance health, safety, and environmentally responsible technologies. Together, our Life Sciences and Industrial teams serve a diverse range of customers including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation industries. Our industry-leading technologies and solutions are at work in countless applications, protecting critical operating assets, improving product quality, safeguarding the health, and minimizing emissions and waste
For more info, please check: https://www.pall.com/en/biotech.html
SaniSure is a global leader in the design and manufacturing of single-use systems and components for drug and vaccine manufacturing and other biotech and pharmaceutical applications. With the consolidation of several strategic acquisitions under one integrated roof, the combined resources, competencies and ability to create value for customers is unmatched in the industry. SaniSure’s core manufacturing capabilities include cleanroom assembly, fabrication, injection molding, injection stretch blow molding, tubing extrusion, filling-needle manufacturing, and many additional proprietary technologies.
SaniSure offers a wide range of single-use technology systems and components including Mixed4Sure™ mixing solutions, complex sterile assemblies, PharmaTainer™ bottles and carboys, Cap2V8® bottle closures, Pharma-Clear® Silicone Tubing, Cellgyn® TPE tubing, Pharma- Line™ tubing, aSURE® fittings, and many more.
SaniSure has a growing global footprint of five engineering and manufacturing sites worldwide to provide customers with an unrivaled level of innovation, quality, and vertical integration/supply-chain security.
Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions support our customers in producing drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety Globally trusted for quality and precision, Terumo Pharmaceutical Solutions offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services, for primary container, injection, infusion therapy devices, and contract development and manufacturing services (CDMO).
We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral
drug delivery. Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies for
all parenteral applications. We provide sterile injectable contract development and manufacturing (CDMO) services from initial combination device design and formulation development to commercial manufacturing.
supporting better patient outcomes around the world.
We listen. We question. We deliver.
Networking Package for solution Providers
- Limited availability
- Secure 2 Delegate Passes and unlock two additional exclusive 1:1 Meetings!
Service & Solutions Providers
- Limited Super valid until the 31st October 2023
Biopharma (Academic & Research Institutes)
- Limited Super valid until the 31st October 2023